GILEAD SCIENCES 885823 (Seite 356)

eröffnet am 20.02.06 13:18:36 von
neuester Beitrag 18.11.20 20:11:25 von

Beitrag schreiben

Begriffe und/oder Benutzer


29.10.20 16:23:59
Beitrag Nr. 3.551 ()
Ja,so ist es mit den Lügen,unser Placebo ist nichts wert und so wird der Kurs wohl weiter in der Versenkung verschwinden,es ja bald die riesige Dividende da aber bis dahin ist der Kurs bei 40€.
Gilead Sciences | 57,92 $
30.10.20 10:06:54
Beitrag Nr. 3.552 ()
Ich kaufe jetzt nach. Wenn mir jemand seine Aktien schenken möchte, weil die für ihn nichts Wert sind: Deal!…
Gilead Sciences | 49,07 €
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
31.10.20 07:58:49
Beitrag Nr. 3.553 ()
Hier glaubt doch niemand mehr an die Auferstehung dieses Geldvernichters
Gilead Sciences | 58,15 $
01.11.20 10:00:38
Beitrag Nr. 3.554 ()
Antwort auf Beitrag Nr.: 65.546.104 von Trader_Kid am 30.10.20 10:06:54
Zitat von Trader_Kid: Ich kaufe jetzt nach. Wenn mir jemand seine Aktien schenken möchte, weil die für ihn nichts Wert sind: Deal!…

Hm, ... :rolleyes:

"Remdesivir was seen as one of the brightest hopes in the dark days of March and April, when doctors had few tools to treat a new disease and families rushed to gain access to the drug in a desperate gambit to save their dying relatives.

More than six months later, enthusiasm has fizzled. One large, government-run trial showed that the drug shortens patients’ recovery times, but the two other studies the F.D.A. used to justify its approval — sponsored by Gileaddid not compare the treatments with a placebo, the gold standard for evaluating a drug. No studies have shown that it significantly lowers death rates.

And just days before the F.D.A. granted approval, a large study sponsored by the World Health Organization found that remdesivir provided no benefit to hospitalized patients.

“I think most people think that because a drug is F.D.A. approved, that means it must work,” said Dr. Aaron S. Kesselheim, a professor of medicine at Harvard Medical School who studies the drug industry. He and other researchers recently found that less than one-third of new drugs approved by the F.D.A. and its European counterpart over the past decade were rated as having a “high therapeutic value” by outside experts.

“I think it’s important to recognize that F.D.A. approval doesn’t guarantee a certain level of benefit — all it says is that there is some benefit,” he said.

On a call with investors on Wednesday, Gilead’s chief executive, Daniel O’Day, said remdesivir had a role to play, along with vaccines and other treatments.

“There’s a lot we don’t know about the pandemic, of course, but I think what we do know is that in order to get us all back to normal, this is going to take a variety of approaches,” he said. “We’re proud to be at the front end of this with a very potent antiviral.”

ImageGilead Sciences’ headquarters in Foster City, Calif. The company said remdesivir had brought in $873 million in revenues so far this year.

Remdesivir was originally developed as a treatment for Ebola and hepatitis C and is thought to interfere with the reproduction of viruses by jamming itself into new viral genes.

Because it had previously shown promise in animal studies of other coronaviruses, it was almost immediately seen as a possible answer for Covid-19. Gilead rushed emergency doses to China and began ramping up manufacturing.

The drug was initially used on the very sick, but has since been found to work better earlier in the course of the disease. It is routinely given as a five-day treatment to people who are hospitalized for Covid-19, including to President Trump when he was infected earlier this month.

Gilead has come under criticism for its efforts to profit from the drug. In March, when there were still fewer than 200,000 cases of Covid-19, the company applied to the F.D.A. to label remdesivir as an orphan drug, a designation that provides tax and other incentives to companies developing products for rare diseases. After a public outcry, it asked the F.D.A. to rescind its application."

Gilead Sciences | 49,92 €
01.11.20 12:12:45
Beitrag Nr. 3.555 ()
Gilead is more than Remdesivir.
And even though if Remdesivir does not meet highest expectations, it helps for top - and bottom line.
Maybe Gilead is not too good for daytraders with short term goal, but I believe it is a solid long term investment with the additional potential of extra business due to corona.
Gilead Sciences | 49,92 €
01.11.20 12:48:00
Beitrag Nr. 3.556 ()
Gilead Sciences | 49,92 €
16.11.20 16:36:34
Beitrag Nr. 3.557 ()
Nach dem nächsten Erfolg einer Firma in Sachen Impfstoff ist wohl klar das Remd. nur ein Placebo ist😂
Gilead Sciences | 61,22 $
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
16.11.20 23:54:46
Beitrag Nr. 3.558 ()
Antwort auf Beitrag Nr.: 65.724.720 von Worky2 am 16.11.20 16:36:34😴😴😴
Gilead Sciences | 61,09 $
17.11.20 07:48:12
Beitrag Nr. 3.559 ()
DIESER GANZE Laden ist langweilig
Gilead Sciences | 61,09 $
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
17.11.20 09:37:35
Beitrag Nr. 3.560 ()
Antwort auf Beitrag Nr.: 65.731.893 von Worky2 am 17.11.20 07:48:12ach worky,
was soll man von dir halten? unglaublich welche energie und wie viel zeit du aufbringst um deine überflüssigen weisheiten und ergüsse hier abzuladen. was versprichst du dir davon? muss schon ein ziemlich langweiliges, erbärmliches leben sein. zum Glück gibts ja die ignore funktion.
Schönes Leben noch
Gilead Sciences | 51,36 €

Beitrag zu dieser Diskussion schreiben